ARV-806 — Initial data
H2 2026
◦ Reiterated plan to share initial data from the Phase 1 monotherapy dose escalation clinical trial in the second half of 2026.Source filing
ARVN biotech catalysts & pipeline
ARVINAS INC · Data as of 2026-10-25
Upcoming catalysts
ARV-027 — Initial data
1H 2027
• Continue enrollment in the multiple dose cohort of the Phase 1 clinical trial in healthy volunteers and share initial data evaluating androgen receptor (AR)-degradation in muscle (1H 2027).Source filing
ARV-393 — Initial data
mid-2027
◦ Share data from the combination cohort with glofitamab in patients with DLBCL in the ongoing Phase 1 clinical trial (mid-2027).Source filing
ARV-393 — Conference presentation
H2 2026
We plan to share clinical data from the early monotherapy cohorts in the ongoing Phase 1 dose escalation clinical trial of ARV-393 in patients with relapsed/refractory NHL at a medical congress in the second half of 2026.Source filing